Displaying drugs 16176 - 16200 of 16245 in total
Bisegliptin
Bisegliptin is a compound for the treatment of type 2 diabetes. It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion and lowering blood glucose levels without hypoglycemic effects.
Investigational
Matched Description: … blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion and …
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine
25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist. It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion . It was discovered in 2014 at the University of Copenhagen.
Experimental
Matched Description: … It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects …
CY-1503
CY-1503 is a pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-Dglucopyranosyl unit, and one alpha-L-fucopyranosyl unit. It was investigated in cardiopulmonary bypass during surgical repair of congenital heart lesions.
Investigational
Matched Description: … as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-Dglucopyranosyl unit, and …
Carbon black
Produced by the incomplete combustion of hydrocarbons, carbon black is an insoluble pigment with demonstrated adverse effects on pulmonary function. Upon inhalation, carbon black has been reported to trigger an inflammatory response in the lung tissue and has been linked to carcinogenicity.[A263406, A263411, A263416]
Investigational
Matched Description: … inhalation, carbon black has been reported to trigger an inflammatory response in the lung tissue [A263401] and …
VSF-173
VSF-173 is an oral small molecule. It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect. It is developed for the treatment of excessive sleepiness. Study shows that VSF-173 possesses a novel mechanism to address disorders of excessive...
Investigational
Matched Description: … It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression …
CHF 4227
CHF 4227 is a new selective estrogen receptor modulator (SERM). The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used...
Investigational
Matched Description: … The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone …
Avasopasem manganese
Avasopasem manganese, also known as GC4419, is a highly-selective small molecule mimetic of superoxide dismutase (SOD) being investigated for the reduction of radiation-induced severe oral mucositis.[L27246, L27256] This drug has potential application for radiation-induced esophagitis and oral mucositis, in addition to being currently tested against COVID-19.
Investigational
Matched Description: … [L27246, L27256] This drug has potential application for radiation-induced esophagitis and oral mucositis …
R411
R411 is a non-steroid oral medicine for the treatment of asthma. It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation. It is a dual-acting competitive integrin antagonist (as compared to previously developed single integrin antagonists or SIAs) that prevents binding of V-CAM1 to...
Investigational
Matched Description: … It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory …
Murizatoclax
Investigational
Matched Iupac: … (1S,3'R,6'R,7'R,8'E,11'S,12'R)-7'-{[(9aR)-octahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methyl}-6-chloro-7'- …
DT2216
Investigational
Matched Iupac: … (2S,4R)-1-[(2S)-2-(7-{4-[(3R)-3-{[4-({[4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl …
ND1251
ND1251 is an orally active phosphodiesterase-4 (PDE4) inhibitor, a mechanism clinically proven to play a role in alleviating symptoms of depression. ND1251 is a very potent compound with a large safety margin. ND1251 may also have applications in other disorders, such as Alzheimer's disease, mild cognitive impairment, multiple sclerosis and...
Investigational
Matched Description: … applications in other disorders, such as Alzheimer's disease, mild cognitive impairment, multiple sclerosis and …
Delta-2-Albomycin A1
Experimental
Matched Iupac: … (8S,11R,14R)-14-amino-8-{[(1S)-1-{[(1R,2R)-2-[(2R,3S,4S,5R)-5-[(4Z)-4-(carbamoylimino)-3-methyl-2-oxo …
Nifurpirinol
Experimental
Vet approved
ATX-201
ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic
keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their...
Investigational
Matched Description: … The Company determined that the program was not meeting their expected primary and exploratory objectives …
NV-18
NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer. Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma...
Investigational
Matched Description: … almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and …
Sirna-027
Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular...
Investigational
Matched Description: … Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. …
DG051
DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4...
Investigational
Matched Description: … attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and …
Dotamtate Pb-212
Investigational
Matched Iupac: … hydroxypropyl]-C-hydroxycarbonimidoyl}-6,9,12,15,18-pentahydroxy-7-[(1R)-1-hydroxyethyl]-13-[(1H-indol-3- …
Hexamethonium
A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by...
Experimental
Matched Description: … It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. …
XMT-1001
XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity. It is a water-soluble macromolecular conjugate of camptothecin (CPT). In this novel CPT pro-drug, CPT is conjugated with a 70 kDa biodegradable hydrophilic polyacetal, poly (1-hydroxymethylene hydroxylmethylformal). XMT-1001 has demonstrated an improved therapeutic...
Investigational
Matched Description: … XMT-1001 has demonstrated an improved therapeutic window as compared with CPT and irinotecan in human …
Solasonine
Investigational
Matched Iupac: … (2S,3R,4S,5S,6R)-2-{[(2R,3S,4S,5R,6R)-3-hydroxy-2-(hydroxymethyl)-6-[(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R …
CRx-139
CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. The synergistic combination containing low doses of the...
Investigational
Matched Description: … The synergistic combination containing low doses of the glucocorticoid steroid prednisolone and the antidepressant …
1,2-dichlorobenzene
1,2-Dichlorobenzene, also named ortho-dichlorobenzene, is an organic compound. It is a non-polar colorless liquid that is miscible in most organic solvents. This derivative of benzene differs from the parent compound by the presence of two adjacent chlorine atoms. 1,2-dichlorobenzene is used as a precursor for agrochemicals, as a solvent for...
Experimental
Matched Description: … dichlorobenzene is used as a precursor for agrochemicals, as a solvent for fullerenes, as an insecticide and …
CTS-21166
CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent...
Investigational
Matched Description: … currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability, and …
Cobalamin
Experimental
Matched Iupac: … {[(2S)-2-{[(2R,3S,4R,5S)-5-(5,6-dimethyl-1H-1,3-benzodiazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3- …
Displaying drugs 16176 - 16200 of 16245 in total